.png)
Duovir 150/300 mg: Lamivudine and Zidovudine Uses, Side Effects, and Prescription Access
Duovir 150/300 mg is a prescription antiretroviral medicine containing lamivudine 150 mg and zidovudine 300 mg in each tablet. The Duovir brand is marketed by Cipla in India, and the combination is used as part of treatment for human immunodeficiency virus (HIV) infection. Lamivudine and zidovudine belong to a group of HIV medicines called nucleoside reverse transcriptase inhibitors (NRTIs), which interfere with the virus's ability to make new copies of itself. Importantly, Duovir is not a complete HIV treatment by itself; lamivudine/zidovudine is used with other antiretroviral medicines. Zidovudine can also cause important adverse effects, particularly anaemia and neutropenia, so appropriate clinical and laboratory monitoring matters. This guide explains Duovir's uses, general dosage information, side effects, safety precautions, and why legitimate prescription access is important.
What Is Duovir 150/300 mg and How Does It Work?
Duovir contains two antiretroviral medicines in one fixed-dose tablet: lamivudine 150 mg and zidovudine 300 mg. Current Indian listings identify Cipla Ltd as the marketer, while Indian pharmaceutical pricing records also list Duovir in this strength.
Both medicines are NRTIs. After they enter cells, their active forms interfere with HIV reverse transcriptase, an enzyme the virus uses during replication.
By interfering with this process, the medicines help suppress HIV replication. They do not eliminate HIV from the body.
What does each ingredient do?
Lamivudine, often abbreviated as 3TC, has activity against HIV-1. It also has activity against hepatitis B virus (HBV), which creates an important safety consideration for people who have both HIV and hepatitis B.
Zidovudine—also called ZDV or AZT—is another NRTI with activity against HIV. It has been used in HIV medicine for decades, although treatment recommendations have evolved as newer antiretroviral options have become available.
The official lamivudine and zidovudine prescribing information states that the fixed-dose combination is indicated with other antiretroviral agents for HIV-1 infection.
What the two medicines in Duovir contribute to HIV treatment
Ingredient | Strength in Duovir | Medicine class | Main role |
Lamivudine | 150 mg | NRTI | Interferes with HIV replication |
Zidovudine | 300 mg | NRTI | Interferes with HIV replication |
Lamivudine + zidovudine | 150/300 mg | Dual-NRTI combination | Provides two antiretroviral medicines in one tablet |
Duovir contains two active HIV medicines, but two NRTIs alone do not constitute a standard complete treatment regimen. The combination is intended to be used with other appropriate antiretroviral therapy, selected according to the person's HIV treatment plan.
What Is Duovir Used For?
Duovir is used as part of antiretroviral treatment for HIV infection. Its purpose is to help suppress viral replication when combined with other appropriate HIV medicines.
Effective antiretroviral therapy aims to reduce the amount of HIV in the blood—known as viral load—to very low levels while preserving or restoring immune function.
Duovir is not a cure for HIV
Antiretroviral medicines can control HIV very effectively, but they do not remove the virus completely from the body.
Treatment therefore needs to be taken consistently over the long term. Stopping an HIV regimen or repeatedly missing doses can allow viral replication to increase and may contribute to treatment failure and drug resistance.
Is Duovir still commonly used?
HIV treatment has changed substantially since lamivudine/zidovudine combinations were introduced. Newer antiretroviral combinations are now commonly preferred for people starting HIV treatment.
Current U.S. NIH patient information notes that lamivudine/zidovudine remains FDA-approved but is no longer commonly used or recommended as an HIV treatment in the United States. Current recommended initial regimens generally use other combinations, often incorporating an integrase inhibitor.
That does not mean someone already prescribed Duovir should stop it. HIV regimens should be changed only after clinical review because treatment history, resistance, tolerability, other conditions, and available medicines all influence the appropriate regimen.
What Is the Usual Duovir 150/300 mg Dosage?
The dose of lamivudine 150 mg/zidovudine 300 mg in U.S. prescribing information for adults and adolescents weighing at least 30 kg is one tablet taken orally twice daily. This is general reference information, not a personal dosing instruction.
Because Duovir contains fixed amounts of both medicines, it is unsuitable when the individual components need separate dose adjustments.
General dosing and administration considerations for lamivudine 150 mg/zidovudine 300 mg
Situation | General prescribing information | Why it matters |
Adults and adolescents ≥30 kg | One 150/300 mg tablet twice daily in U.S. labeling | Must be used as part of an appropriate HIV regimen |
Children ≥30 kg | Same fixed-dose regimen may be used when the tablet can be swallowed appropriately | Pediatric HIV treatment requires specialist guidance |
Weight below 30 kg | Fixed-dose tablet is not recommended in U.S. labeling | Individual components allow more appropriate dose adjustment |
Significant renal impairment requiring adjustment | Fixed-dose combination may not be appropriate | Lamivudine may require dose adjustment |
Hepatic impairment | Fixed-dose combination is not recommended in U.S. labeling | Zidovudine exposure and dosing may require individual management |
Dose-limiting adverse effects | Separate components may be necessary | Fixed tablet does not allow one ingredient to be reduced independently |
The DailyMed lamivudine/zidovudine dosage guidance provides detailed U.S. prescribing information, including situations in which the fixed-dose tablet is unsuitable.
What happens if you miss a dose?
The U.S. patient information advises taking a missed dose when remembered, but not doubling the next dose or taking more than prescribed.
For someone taking HIV treatment, frequent missed doses deserve discussion with the HIV care team. Practical barriers such as side effects, schedule difficulties, medication access, or interactions may be addressable without stopping treatment.
What Are the Side Effects of Duovir?
Lamivudine/zidovudine can cause both relatively common symptoms and less common but medically important adverse effects. Zidovudine's effects on blood cells are a particularly important consideration.
Potential symptoms reported with lamivudine/zidovudine treatment can include:
Headache
Nausea
Vomiting
Diarrhoea
Abdominal discomfort
Tiredness or weakness
Dizziness
Not every symptom experienced during HIV treatment is necessarily caused by Duovir. HIV itself, other medicines, infections, and underlying medical conditions can produce similar problems.
Anaemia and neutropenia
Zidovudine can suppress bone marrow function.
The U.S. prescribing information carries a boxed warning about haematologic toxicity, including anaemia and neutropenia. These effects are particularly important in people with advanced HIV or pre-existing bone-marrow problems.
Blood counts may therefore need monitoring during treatment.
Symptoms such as unusual tiredness, marked weakness, breathlessness, persistent fever, or frequent infections should be reported to the treating healthcare professional.
Muscle problems
Prolonged zidovudine use has been associated with symptomatic myopathy, meaning disease or weakness affecting muscles. This is also included in the boxed safety information for lamivudine/zidovudine.
Persistent unexplained muscle weakness or pain should therefore be discussed with the treating clinician.
Lactic acidosis and liver problems
Nucleoside analogues, including lamivudine and zidovudine, have been associated with lactic acidosis and severe enlargement of the liver with fatty changes. Rare cases have been fatal.
Symptoms such as unexplained severe weakness, persistent nausea or vomiting, significant abdominal discomfort, breathing difficulty, or signs of liver dysfunction require prompt medical assessment.
What Important Safety Precautions Come With Duovir?
The most important precautions relate to blood-cell abnormalities, liver disease, hepatitis B coinfection, kidney function, medicine interactions, and the inability to adjust the two Duovir ingredients separately.
HIV and hepatitis B coinfection
Lamivudine also acts against hepatitis B virus. This becomes particularly important when someone has both HIV and chronic hepatitis B.
Severe acute hepatitis B exacerbations have been reported after discontinuing lamivudine-containing treatment in people coinfected with HIV and HBV. The prescribing information therefore recommends close liver monitoring after discontinuation.
This is an important reason not to stop Duovir—or another lamivudine-containing HIV regimen—without medical guidance.
Kidney and liver problems
Fixed-dose tablets create a practical limitation: you cannot lower the lamivudine dose without simultaneously changing zidovudine.
U.S. prescribing information therefore does not recommend the fixed combination for people requiring individual dose adjustment, including patients with creatinine clearance below 50 mL/min or hepatic impairment. Separate formulations of the components can be used when appropriate.
Medicine interactions
A healthcare professional should review prescription medicines, over-the-counter medicines, and supplements before treatment.
One notable example is ribavirin. The prescribing information states that coadministration of ribavirin and zidovudine is not advised because worsening anaemia has been reported in people with HIV/HCV coinfection receiving the combination.
Do not stop or change another medicine yourself because of a possible interaction; the complete regimen needs professional review.
How Do You Access Duovir by Prescription?
Duovir is a prescription medicine, and current Indian pharmacy listings identify the lamivudine 150 mg/zidovudine 300 mg Cipla product as requiring a prescription.
Prescription control is particularly important for antiretroviral medicines because HIV treatment should be selected as a complete regimen rather than as individual tablets purchased independently.
Before prescribing or changing HIV treatment, clinicians may consider factors such as:
HIV viral load
CD4 count
Previous antiretroviral treatment
HIV drug-resistance results when relevant
Complete blood count
Hepatitis B status
Other medicines and possible interactions
Pregnancy or pregnancy plans
Previous treatment intolerance
The NIH HIV treatment guidelines provide current evidence-based recommendations for selecting and monitoring antiretroviral therapy.
Why buying HIV medicines without appropriate prescribing is risky
Choosing antiretroviral drugs independently can result in an incomplete or inappropriate regimen. That can expose HIV to medicines without achieving adequate viral suppression and potentially encourage drug resistance.
There is also a risk of missing important safety monitoring, particularly with zidovudine because of its association with anaemia and neutropenia.
If access or affordability is interrupting treatment, contact the prescribing clinic, HIV treatment centre, or pharmacist promptly rather than rationing tablets or substituting another HIV medicine independently.
When Should You Contact a Healthcare Professional?
Contact the HIV care team if side effects are persistent, doses are repeatedly missed, another clinician recommends a new medicine, or there is difficulty obtaining the prescribed antiretroviral regimen.
Prompt medical assessment is particularly important for unusual weakness or breathlessness that could suggest significant anaemia, persistent fever or infections that could accompany neutropenia, significant muscle weakness, or symptoms suggesting liver problems.
Seek urgent medical care for severe allergic symptoms, severe breathing difficulty, fainting, marked confusion, or another serious or rapidly worsening reaction.
People with HIV and hepatitis B coinfection should not abruptly discontinue lamivudine-containing treatment. The prescribing information warns that stopping lamivudine can be followed by severe acute worsening of hepatitis B, requiring clinical and laboratory follow-up.
Conclusion
Duovir 150/300 mg combines lamivudine and zidovudine, two NRTI antiretroviral medicines used as part of combination HIV treatment. Although the combination has an established role in HIV therapy, newer regimens are now commonly preferred in some jurisdictions, and treatment selection should reflect current guidance, previous therapy, resistance, organ function, and individual safety considerations.
Duovir requires a prescription and should not be started, stopped, shared, or substituted without HIV-care guidance. Regular monitoring is particularly important because zidovudine can cause anaemia and neutropenia. If treatment access, missed doses, or side effects are becoming a problem, contact the prescribing HIV service promptly rather than interrupting therapy.
Frequently Asked Questions
1. What is Duovir 150/300 mg used for?
Duovir contains lamivudine 150 mg and zidovudine 300 mg and is used as part of antiretroviral treatment for HIV infection. It helps suppress HIV replication but does not cure HIV. The combination should be used with other appropriate antiretroviral treatment.
2. Is Duovir a complete HIV treatment by itself?
No. Lamivudine/zidovudine contains two NRTIs and is indicated for use with other antiretroviral medicines. The rest of the regimen should be selected by an HIV clinician according to current guidelines, treatment history, resistance, and individual health factors.
3. What is the usual dose of Duovir 150/300 mg?
U.S. prescribing information for lamivudine 150 mg/zidovudine 300 mg lists one tablet twice daily for adults and adolescents weighing at least 30 kg. Individual prescribing may differ, and the fixed combination is unsuitable when separate dose adjustments are required.
4. Can Duovir cause anaemia?
Yes. Zidovudine can cause bone-marrow suppression, including anaemia and neutropenia, and this risk appears in the medicine's boxed warning. Clinicians may monitor blood counts, particularly when risk is higher. Significant weakness, breathlessness, fever, or recurrent infections should be reported.
5. Can I stop Duovir if I develop side effects?
Do not stop an HIV regimen on your own unless emergency medical care directs otherwise. Interrupting antiretroviral treatment can allow HIV replication to increase, while stopping lamivudine can also worsen hepatitis B in people with HBV coinfection. Contact your HIV care team promptly about troublesome side effects.
6. Can I buy Duovir without a prescription?
Duovir is listed as a prescription medicine in India. Antiretroviral treatment should be supplied through legitimate prescription channels because the complete regimen, interactions, laboratory monitoring, and treatment history need to be considered rather than purchasing individual HIV medicines independently.
Comments